Shiaw-Yih (Phoebus) Lin, Ph.D.

Peer-Reviewed Articles

1. McGrail DJ, Li Y, Smith RS, Feng B, Dai H, Hu L, Dennehey B, Awasthi S, Mendillo ML, Sood AK, Mills GB, Lin SY, Yi SS, Sahni N. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins. Cell Rep Med 4(11):101255, 2023. PMID: 37909041.
2. Zhang J, Dai H, Huo L, Burks JK, McGrail DJ, Lin SY. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway. J Immunother Cancer 11(10):e007560, 2023. PMID: 37907220.
3. Sousa LG, McGrail DJ, Lazar Neto F, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Spardy Burr N, Cooper ZA, Kinneer K, Cortez MA, Lin SY, Bell D, El Naggar A, Burks J, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res 29(16):3162-3171, 2023. PMID: 37256648.
4. Wang Y, Ma J, Lin SY, Xie H, Liang D. A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies. J Pharm Biomed Anal 228:115326, 2023. PMID: 36924633.
5. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL; ICON Team.. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform(6):e2200040, 2022.
6. Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks J, Lin SY, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 10(3):e004371, 2022.
7. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2):e003082, 2022.
8. Shih DJH, Ruoxing L, Müller P, Zheng WJ, Do KA, Lin SY, Carter SL.. CNGPLD: Case-control copy-number analysis using Gaussian process latent difference. Bioinformatics 38(8):2096-101, 2022.
9. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C.. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2021.
10. Shih DJH, Chen MK, Yin J, McGrail DJ, Dai H, Wei R, Zhang J, Zheng WJ, Do KA, Yang L, Hung MC, Lin SY.. Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer. Am J Cancer Res 12(1):337-354, 2022.
11. McGrail DJ, Pilié PG, Dai H, Lam TNA, Liang Y, Voorwerk L, Kok M, Zhang XH, Rosen JM, Heimberger AB, Peterson CB, Jonasch E, Lin SY. Replication stress response defects are associated with response to immune checkpoint blockade in non-hypermutated cancers. Sci Transl Med 13(617):eabe6201, 2021. e-Pub 2021. PMID: 34705519.
12. Lindemann A, Patel AA, Tang L, Tanaka N, Gleber-Netto FO, Bartels MD, Wang L, McGrail DJ, Lin SY, Frank SJ, Frederick MJ, Myers JN, Osman AA. Combined inhibition of Rad51 and Wee1 enhances cell killing in HNSCC through induction of apoptosis associated with excessive DNA damage and replication stress. Mol Cancer Ther 20(7):1257-1269, 2021. e-Pub 2021. PMID: 33947685.
13. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Lim B, Ueno NT, Litton JK, Ferrarotto R, Chang JT, Moulder SL, Lin S-Y. High tumor mutation burden fails to predict immune checkpoint blockade response across solid tumors. Annals of Oncology 32(5):661-672, 2021. e-Pub 2021.
14. Wei R, Dai H, Zhang J, Shih D, Liang Y, Xiao P, McGrail DJ, Lin S-Y. A Gene Expression Signature to Predict Nucleotide Excision Repair Defects and Novel Therapeutic Approaches. Int. J. Mol. Sci 22:5008, 2021.
15. Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D, Frank SJ, Song X, Kupferman ME, Liu B, Lee JJ, Glisson BS, Zhang J, Aster JC, Lin SY, Futreal PA, Heymach JV, El-Naggar AK.. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res 27(3):852-864, 2021.
16. Li Y, Burgman B, McGrail DJ, Sun M, Qi D, Shukla SA, Wu E, Capasso A, Lin SY, Wu CJ, Eckhardt SG, Mills GB, Li B, Sahni N, Yi SS.. Integrated Genomic Characterization of the Human Immunome in Cancer. Cancer Res 80(21):4854-4867, 2020.
17. Zou J, Qin W, Yang L, Wang L, Wang Y, Shen J, Xiong W, Yu S, Song S, Ajani JA, Lin SY, Mills GB, Yuan X, Chen J, Peng G.. Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res 10(11):3947-3972, 2020.
18. Liang Y, Yu L, Zhang D, Zhao X, Gao H, Slagle BL, Goss JA, Wang X, Li K, Lin SY.. BRIT1 dysfunction confers synergistic inhibition of hepatocellular carcinoma by targeting poly (ADP-ribose) polymerases and PI3K. Am J Cancer Res 10(6):1900-1918, 2020.
19. Wang J, McGrail D, Bhupal P, Zhang W, Lin K-Y, Ku Y, Lin T, Wu H, Tsai K, Li K, Peng C-Y, Finegold M, Lin SY, and Tsai R. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress. Molecular Cancer Research 18(5):723-734, 2020. e-Pub 2020.
20. Liu XD, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H, Beckermann KE, Haake SM, Isgandrova S, Martinez-Moczygemba M, Sahni N, Tannir NM, Lin SY, Rathmell WK, Jonasch E.. PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nat Commun 11(1):2135, 2020.
21. McGrail D, Garnett J, Yin J, Dai H, Shih D, Lam TNA, Li Y, Sun C, Li Y, Schmandt R, Wu JY, Hu L, Liang Y, Peng G, Jonasch E, Menter D, Yates MS, Kopetz S, Lu K, Broaddus R, Mills GB, Sahni N & Lin SY. Proteome instability is a therapeutic vulnerability in mismatch repair deficient cancer. Cancer Cell 37(3):371-386, 2020. e-Pub 2020.
22. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB.. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867, 2019.
23. Lin T, Lin TC, McGrail DJ, Bhupal PK, Ku YH, Zhang W, Meng L, Lin SY, Peng G, Tsai RYL. Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression. Oncogene 38(20):3919-3931, 2019.
24. Jiang Y, Dai H, Li Y, Yin J, Guo S, Lin SY, McGrail DJ. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Int J Cancer 144(5):1092-1103, 2019.
25. McGrail DJ, Lin CC, Dai H, Mo W, Li Y, Stephan C, Davies P, Lu Z, Mills GB, Lee, JS, Lin SY. Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. Cell Rep 23:2095–2106, 2018.
26. Li Y, Liu Q, McGrail D, Dai H, Li K, Lin SY. CHD4 mutations promote endometrial cancer stemness by activating TGF-beta signaling. Am J Cancer Res 8(5):903-914, 2018.
27. McGrail DJ, Federico L, Li Y, Dai H, Lu Y, Mills GB, Yi S, Lin SY, Sahni N.. Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9(1):1317, 2018.
28. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416, 2018.
29. Li Y, Sahni N, Pancsa R, McGrail DJ, Xu J, Hua X, Coulombe-Huntington J, Ryan M, Tychhon B, Sudhakar D, Hu L, Tyers M, Jiang X, Lin SY, Babu MM, Yi S.. Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer. Cell Rep 21(3):798-812, 2017.
30. Wang W, Zhao J, Wen X, Lin C C-J, Li J, Huang Q, Yu Y, Lin S-Y, and Li C.. MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media & Molecular Imaging 2017, 2017.
31. Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Sci Transl Med 9(392):eaal5148, 2017.
32. Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS, Li K.. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene 36(20):2910-2918, 2017.
33. Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, Wang J, Lu Y, Byers LA, Perou CM, Lin SY, Mills GB.. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Sci Adv 3(4):e1600957, 2017.
34. McGrail DJ, Lin CCJ, Garnett J, Liu Q, Mo W, Dai H, Lu Y, Yu Q, Ju Z, Yin J, CP Vellano CP, Hennessy B, Mills GB, & Lin S-Y. Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. npj Systems Biology and Applications 3:Article number:8, 2017.
35. Mo W, Liu Q, Lin CC-J, Dai H, Peng Y, Liang Y, Peng G, Meric-Bernstam F, Mills GB, Li K, Lin S-Y. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res 22(7):1699-1712, 2016. e-Pub 2015.
36. Huang S, Tu W, Ju Z, Poage GM, Cai CR, Brewster A, Lin S-Y, Mills GB, Wang H and Peng G. A Five-Gene Signature Inferred from Transcriptome Profiling of Homologous Recombination-Mediated DNA Repair Predicts Clinical Outcome of Patients with Cancer. Jacobs Journal of Biomarkers 2(1), 2016.
37. Kim JL, Ha GH, Campo L, Denning MF, Patel TB, Osipo C, Lin SY, Breuer EK. The role of Rak in the regulation of stability and function of BRCA1. Oncotarget 8(49):86799-86815, 2015. e-Pub 2015. PMID: 26513018.
38. Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R, Xia Y, Chen Q, Peng G, Lin SY, Lu Z. Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 17(9):1158-68, 2015. PMID: 26237645.
39. Liang Y, Gao H, Lin SY, Goss JA, Du C, Li K. Mcph1/Brit1 deficiency promotes genomic instability and tumor formation in a mouse model. Oncogene 34(33):4368-78, 2015. PMID: 25362854.
40. Lee HJ, Lan L, Peng G, Chang WC, Hsu MC, Wang YN, Cheng CC, Wei L, Nakajima S, Chang SS, Liao HW, Chen CH, Lavin M, Ang KK, Lin SY, Hung MC. Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response. Cell Res 25(2):225-36, 2015. PMID: 25601159.
41. Peng Y, Dai H, Wang E, Lin CC, Mo W, Peng G & Lin S-Y. TUSC4 functions as a tumor suppressor by regulating BRCA1’s stability via the E3 ubiquitination pathway. Cancer Research 75(2):378-386, 2015. e-Pub 2014. PMID: 25480944.
42. Gong L, Govan J, Evans E, Dai H, Wang E, Lee S-Y, Li J, Lin HK, Lazar A, Mills GB and Lin S-Y. Nuclear PTEN tumor-suppressive functions through maintaining normal heterochromatin structure. Cell Cycle 14(14):2323-32, 2015.
43. Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2014. PMID: 24553445.
44. Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, Wang G, Peng G, Lin S-Y.. BRIT1 Regulates p53 Stability and Functions as a Tumor Suppressor in Breast Cancer. Carcinogenesis 34(10):2271-2280, 2013. PMID: 23729656.
45. Tian F, Sharma S, Zou J, Lin S-Y, Wang B, Rezvani K, Wang H, Parvin JD, Ludwig T, Canman CE, Zhang D.. BRCA1 promotes the ubiquitination of PCNA and recruitment of translesion polymerases in response to replication blockade. Proc. Natl. Acad. Sci U S A 110(33):13558-63, 2013. PMID: 23901102.
46. Meng L, Lin T, Peng G, Hsu J, Lee S, Lin S-Y, Tsai R.. Nucleostemin Deletion Reveals An Essential Mechanism That Maintains The Genomic Stability of Stem and Progenitor Cells. Proc Natl Acad Sci U S A 110(28):11415-20, 2013. PMID: 23798389.
47. Hu R, Wang E, Peng G, Dai H, Lin S-Y.. Zinc Finger Protein 668 interacts with Tip60 to promote H2AX acetylation after DNA damage. Cell Cycle 12(13):2033-41, 2013. PMID: 23777805.
48. Trinh BQ, Ko SY, Barengo N, Lin SY, Naora H.. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs. Cancer Research 73(2):1000-10, 2013. PMID: 23222298.
49. Park YY, Jung SY, Jennings NB, Rodriguez-Aguayo C, Peng G, Lee SR, Kim SB, Kim K, Leem SH, Lin SY, Lopez-Berestein G, Sood AK, Lee JS. FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair. Carcinogenesis 33(10):1843-53, 2012. PMID: 22581827.
50. Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY. Human Nuclease/helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Res 72(11):2802-13, 2012. PMID: 22491672.
51. Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor treatment. J Biol Chem 287(9):6764-72, 2012. PMID: 22219182.
52. Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-34, 2011. PMID: 21852383.
53. Zhang W, Peng G, Lin SY, Zhang P. DNA damage response is suppressed by the high cyclin-dependent kinase 1 activity in mitotic mammalian cells. J Biol Chem 286(41):35899-905, 2011. PMID: 21878640.
54. Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J Biol Chem 286(32):28599-607, 2011. PMID: 21676867.
55. Seviour EG, Lin SY. The DNA damage response: Balancing the scale between cancer and ageing. Aging (Albany NY) 2(12):900-7, 2010. PMID: 21191148.
56. Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, Parker-Thornburg J, Shackleford TJ, Dai H, Lin SY, Lozano G, Rassidakis GZ, Claret FX. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene 29(46):6125-6137, 2010. PMID: 20802511.
57. Ishiguro T, Avila H, Lin SY, Nakamura T, Yamamoto M, Boyd DD. Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. Br J Cancer 102(4):774-782, 2010. PMID: 20087350.
58. Liang Y, Gao H, Lin SY, Peng G, Huang X, Zhang P, Goss JA, Brunicardi FC, Multani AS, Chang S, Li K. BRIT1/MCPH1 is Essential for Mitotic and Meiotic Recombination DNA Repair and Maintaining Genomic Stability in Mice. PLoS Genet 6(1):e1000826, 2010. PMID: 20107607.
59. Liang Y, Gao H, Lin SY, Goss JA, Brunicardi FC, Li K. siRNA-Based Targeting of Cyclin E Overexpression Inhibits Breast Cancer Cell Growth and Suppresses Tumor Development in Breast Cancer Mouse Model. PLoS One 5(9):e12860, 2010. PMID: 20877462.
60. Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, Hu R, Li K, Lin SY. BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Nat Cell Biol 11(7):865-872, 2009. PMID: 19525936.
61. Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, Lin SY, Safari A, Liu D, Songyang Z. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol 16(4):372-379, 2009. PMID: 19287395.
62. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function. Cancer Cell 15(4):304-314, 2009. PMID: 19345329.
63. Rai R, Phadnis A, Haralkar S, Badwe RA, Dai H, Li K, Lin S-Y. Differential regulation of centrosome integrity by DNA damage response proteins. Cell Cycle 7(14):2225-33, 2008. PMID: 18635967.
64. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 103(41):15014-9, 2006. PMID: 17018644.
65. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10(2):145-57, 2006. PMID: 16872911.
66. Lin SY, Rai R, Li K, Xu ZX, Elledge SJ. BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. Proc Natl Acad Sci U S A 102(42):15105-9, 2005. PMID: 16217032.
67. Lin SY, Li K, Stewart GS, Elledge SJ. Human Claspin works with BRCA1 to both positively and negatively regulate cell proliferation. Proc Natl Acad Sci U S A 101(17):6484-6489, 2004. PMID: 15096610.
68. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E overexpressing hepatocellular carcinoma. Cancer Res 63(13):3593-3597, 2003. PMID: 12839946.
69. Lin SY, Elledge SJ. Multiple Tumor Suppressor Pathways Negatively Regulate Telomerase. Cell 113(7):881-889, 2003. PMID: 12837246.
70. Deng J, Miller SA, Wang HY, Xia W, Wen Y, Zhou BP, Li Y, Lin SY, Hung MC. beta-catenin interacts with and inhibits NF-kappa B in human colon and breast cancer. Cancer Cell 2(4):323-34, 2002. PMID: 12398896.
71. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3(9):802-8, 2001. PMID: 11533659.
72. Lin SY, Xia W, Wang JC, Kwong KY, Spohn B, Wen Y, Pestell RG, Hung MC. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A 97(8):4262-6, 2000. PMID: 10759547.
73. Zhou BP, Hu MC, Miller SA, Yu Z, Xia W, Lin SY, Hung MC. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem 275(11):8027-31, 2000. PMID: 10713122.
74. Wen Y, Yan DH, Spohn B, Deng J, Lin SY, Hung MC. Tumor suppression and sensitization to tumor necrosis factor alpha-induced apoptosis by an interferon-inducible protein, p202, in breast cancer cells. Cancer Res 60(1):42-6, 2000. PMID: 10646849.
75. Shao R, Hu MC, Zhou BP, Lin SY, Chiao PJ, von Lindern RH, Spohn B, Hung MC. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IkappaB kinases and nuclear factor kappaB activities. J Biol Chem 274(31):21495-8, 1999. PMID: 10419449.
76. Black AR, Jensen D, Lin S-Y, Azizkhan JC. Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem 274(3):1207-15, 1999. PMID: 9880488.
77. Kiyokawa N, Lee EK, Karunagaran D, Lin SY, Hung MC. Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. J Biol Chem 272(30):18656-65, 1997. PMID: 9228035.
78. Lin S-Y, Black AR, Kostic D, Pajovic S, Hoover CN, Azizkhan JC. Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction. Mol Cell Biol 16(4):1668-75, 1996. PMID: 8657142.

Invited Articles

1. Tiwari A, Trivedi R, Lin SY. Tumor microenvironment: barrier or opportunity towards effective cancer therapy. J Biomed Sci 29(1):83, 2022. PMID: 36253762.
2. Lin RA, Lin JK, Lin SY. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. Kaohsiung J Med Sci 37(6):448-458, 2021. e-Pub 2021. PMID: 33636043.
3. Zhang J, Shih DJH, Lin SY. Role of DNA Repair Defects in Predicting Immunotherapy Response. Biomark Res 8(23), 2020.
4. Lin JK, Lin SY. Leveraging immunogenic cell death to potentiate immune checkpoint therapy in cancer. Trends in Cancer Res 15, 2020.
5. Pan MR, Li K, Lin SY, Hung WC. Connecting the Dots: From DNA Damage and Repair to Aging. Int J Mol Sci 17(5):685, 2016.
6. Peng Y, Wang E, Peng G, and Lin SY. Ubiquitination assay for mammalian cells. Bio-protocol 6(14):e1880, 2016.
7. IP CKM, Yin J, Ng PKS, Lin SY, Mills GB. Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. AIMS Medical Science 3(4):386-416, 2016.
8. Wang SH, Lin SY.. Tumor dormancy: potential therapeutic target in tumor recurrence and metastasis prevention. Exp Hematol Oncol 2(1):19, 2013.
9. Wang E, Lin SY. Brit1 regulates DNA damage repair and chromosome dynamics to suppress tumor phenotypes. Trends in Cancer Research 8:1-10, 2012.
10. Lin SY, Liang Y, Li K. Multiple Roles of BRIT1/MCPH1 in DNA Damage Response, DNA Repair, and Cancer Suppression. Yonsei Med J 51(3):295-301, 2010. PMID: 20376879.
11. Peng G, Lin, S-Y. BRIT1/MCPH1 is a multifunctional DNA damage responsive protein mediating DNA repair-associated chromatin remodeling. Cell Cycle 8(19):3071-3072, 2009.
12. Peng G, Lin SY. The linkage of chromatin remodeling to genome maintenance: contribution from a human disease gene BRIT1/MCPH1. Epigenetics 4(7):457-461, 2009. PMID: 19829069.
13. Yim EK, Siwko S, Lin SY. Exploring Rak tyrosine kinase function in breast cancer. Cell Cycle 8(15):2360-2364, 2009. PMID: 19597351.
14. Liang Y, Lin SY, Brunicardi FC, Goss J, Li K. DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment. World J Surg 33(4):661-666, 2009. PMID: 19034564.
15. Jackson-Bernitsas D, Li K, Lin S-Y. BRIT1 gene in cancer. Encyclopedia of Cancer Springer 2:428-430, 2008.
16. Rai R, Peng G, Li K, Lin S-Y. DNA damage response: the players, the network and the role in tumor suppression. Cancer Genomics Proteomics 4(2):99-106, 2007. PMID: 17804872.
17. Chaplet M, Rai R, Jackson-Bernitsas D, Li K, Lin SY. BRIT1/MCPH1: a guardian of genome and an enemy of tumors. Cell Cycle 5(22):2579-83, 2006. PMID: 17172830.
18. Lin, S-Y, Hung M-C. Cancer: Current concepts. J. Clinical Ligand Assay 22:1-5, 1999.

Editorials

1. Evans E and Lin S-Y. New insights into tumor dormancy: Targeting DNA repair pathways. World J Clin Oncol 6(5):80-88, 2015.
2. Davis JD, Lin SY. DNA damage and breast cancer. World J Clin Oncol 2(9):329-338, 2011. PMID: 21909479.
3. Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2(2):73-79, 2011. PMID: 21603316.

Book Chapters

1. Gong L, Wang E, Lin SY. Chromatin Remodeling in DNA Damage Response and Human Aging. In: Chromatin Remodeling. Intech, 153-171, 2013.
2. Green L, Lin SY. DNA Damage Response and Breast Cancer: An Overview. In: Breast Cancer Cells / Book 2. InTech, 97-112, 2012.
3. Peng G, Lin S-Y. A Novel DNA Damage Responsive Protein Dysfunctioned in Primary Microcephaly and Cancer. In: New Research on DNA Damage. Nova Publishers, 99-112, 2008.
4. Azizkhan JC, Lin S-Y, Jensen D, Kostic D and Black AR. Retinoblastoma protein, gene expression, and cell cycle control. In: Cancer Genes: Functional Aspects. Plenum: New York, 1996.

Letters to the Editor

1. McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB, Ueno NT, Ferrarotto R, Chang JT, Lin SY.. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Ann Oncol 33: 1204-1206, 2022.